Francisco Gimenez is Partner at 8VC and focuses on Bio-IT investments. He received his Ph.D. from Stanford in Biomedical Informatics and B.S. in Electrical Engineering and Computer Sciences from UC Berkeley. In this episode, Francisco explains how breakthroughs in AI, gene editing, and cell therapies converged to jumpstart a new age in biology. He predicts that biomanufacturing platforms, armed with mountains of data and new tools, will bring down the costs of creating and commercializing drugs so smaller companies can treat rarer diseases and deliver more personalized cures. By decentralizing the pharma industry, Francisco is optimistic that the future of medicine will evolve from reactive care to preventative medicine that will help people fully self-actualize and lead their best, healthiest lives. [Joe is a founding partner of 8VC, his venture capital firm.]
Joe Lonsdale: American Optimist
American Optimist, hosted by Joe Lonsdale: entrepreneur, investor, and founder of four multi-billion dollar companies and other mission-driven organizations. American Optimist is an alternative to the fear, cynicism, and zero-sum thinking in mainstream media. Learn from the innovators and leaders who are solving our nation’s most pressing challenges, and doing it in a way that will lift everyone up. Hope should dominate our discourse, and American Optimist will show you why.
American Optimist, hosted by Joe Lonsdale: entrepreneur, investor, and founder of four multi-billion dollar companies and other mission-driven organizations. American Optimist is an alternative to the fear, cynicism, and zero-sum thinking in mainstream media. Learn from the innovators and leaders who are solving our nation’s most pressing challenges, and doing it in a way that will lift everyone up. Hope should dominate our discourse, and American Optimist will show you why.Listen on
Substack App
RSS Feed
Appears in episode
Joe Lonsdale
Recent Episodes
Share this post